Search Our Scientific Publications & Authors

J Oncol Pharm Pract 2018 Dec 7;24(8):617-622. Epub 2017 Aug 7.

Pharmacy Department, Froedtert & The Medical College of Wisconsin, Milwaukee, WI, USA.

Purpose: Ambulatory administration of chemotherapy provides benefit to patients and institutions alike. We hypothesized that transitioning rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (R-EPOCH) from an inpatient to ambulatory setting would reduce inpatient bed days and overall healthcare costs. The purpose of this effort was to create a guideline that would transition R-EPOCH to the ambulatory setting. Read More

J Am Vet Med Assoc 2011 Feb;238(4):501-6

The Animal Medical Center, 510 E 62nd St, New York, NY 10065, USA.

Objective: To evaluate factors associated with second remission in dogs with lymphoma retreated with a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) protocol after relapse following initial treatment with a first-line 6-month CHOP protocol.

Design: Retrospective case series.

Animals: 95 dogs with lymphoma. Read More

J Bronchology Interv Pulmonol 2019 10;26(4):e65-e67

Department of Medicine, Division of Pulmonary and Critical Care Medicine.

J Oncol Pract 2019 08 17;15(8):e644-e651. Epub 2019 Jun 17.

1University of Texas Southwestern Medical Center, Dallas, TX.

Purpose: EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) -based chemotherapy is traditionally administered inpatient because of its complex 96-hour protocol and number of involved medications. These routine admissions are costly, disruptive, and isolating to patients. Here, we describe our experience transitioning from inpatient to outpatient ambulatory EPOCH-based chemotherapy in a safety-net hospital, associated cost savings, and patient perceptions. Read More